Halperin A K, Gross K M, Rogers J F, Cubeddu L X
Clin Pharmacol Ther. 1984 Dec;36(6):750-8. doi: 10.1038/clpt.1984.253.
Twenty-four subjects with mild to moderate essential hypertension completed this 9-wk parallel, randomized, double-blind study of the antihypertensive effects of verapamil (V) (240 to 480 mg%) and propranolol (P) (120 to 360 mg%). V lowered systolic and diastolic blood pressures in all postural positions, with an average reduction of 20/16 mm Hg. With the exception of standing systolic blood pressure, P also lowered systolic and diastolic blood pressures in all postural positions, with an average reduction of 9/11 mm Hg. Differences between V and P were significant only for sitting systolic blood pressure. Heart rate was decreased by P but was not affected by V. The PR interval was prolonged by V. Plasma levels of V and P were directly related to dose. Plasma levels of V were linearly related to those of its major metabolite, norverapamil (r = 0.81). There was no correlation between clinical response and the dose or plasma level of V or P, but all subjects who received 480 mg% V had an average blood pressure reduction of 20/16 mm Hg and plasma levels of the parent drug above 200 ng/ml. V is an effective antihypertensive for mild to moderate essential hypertension. Constipation, pedal edema, and a maculopapular rash were reported as side effects of V.
24名轻度至中度原发性高血压患者完成了这项为期9周的平行、随机、双盲研究，该研究旨在探究维拉帕米（V）（240至480mg%）和普萘洛尔（P）（120至360mg%）的降压效果。V可降低所有体位的收缩压和舒张压，平均降低20/16mmHg。除站立位收缩压外，P也可降低所有体位的收缩压和舒张压，平均降低9/11mmHg。V和P之间的差异仅在坐位收缩压方面具有显著性。P可使心率降低，但V对心率无影响。V可使PR间期延长。V和P的血浆水平与剂量直接相关。V的血浆水平与其主要代谢产物去甲维拉帕米呈线性相关（r = 0.81）。临床反应与V或P的剂量或血浆水平之间无相关性，但所有接受480mg% V的受试者平均血压降低20/16mmHg，母体药物的血浆水平高于200ng/ml。V对轻度至中度原发性高血压是一种有效的降压药物。便秘、足部水肿和斑丘疹皮疹被报告为V的副作用。
